GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » Cash, Cash Equivalents, Marketable Securities

VIA Pharmaceuticals (VIA Pharmaceuticals) Cash, Cash Equivalents, Marketable Securities : $0.08 Mil (As of Dec. 2010)


View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals Cash, Cash Equivalents, Marketable Securities?

VIA Pharmaceuticals's quarterly cash, cash equivalents, marketable securities increased from Jun. 2010 ($0.16 Mil) to Sep. 2010 ($0.28 Mil) but then stayed the same from Sep. 2010 ($0.28 Mil) to Dec. 2010 ($0.08 Mil).

VIA Pharmaceuticals's annual cash, cash equivalents, marketable securities declined from Dec. 2008 ($4.07 Mil) to Dec. 2009 ($2.19 Mil) and declined from Dec. 2009 ($2.19 Mil) to Dec. 2010 ($0.08 Mil).


VIA Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for VIA Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIA Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Chart

VIA Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.34 23.10 4.07 2.19 0.08

VIA Pharmaceuticals Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.19 0.50 0.16 0.28 0.08

VIA Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


VIA Pharmaceuticals  (GREY:VIAP) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


VIA Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
750 Battery Street, Suite 330, San Francisco, CA, USA, 94111
VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.
Executives
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p. 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp 10 percent owner 750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright officer: V.P. ? Finance, Controller 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen director, officer: CEO and President 750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson director 14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub officer: SVP, Research & Development 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun officer: Chief Medical Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd 10 percent owner, other: Possible Member of 10% Group BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus